TRCT
QNTM

Tower Research Capital (TRC)’s Quantum Biopharma Class B Subordinate Voting Shares QNTM Stock Holding History

Tower Research Capital (TRC)’s Portfolio QNTM Stock Details QNTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-71
Closed -$343 – 5744
2026
Q1 		$343 Buy
+71
New +$320 ﹤0.01% 4903
2025
Q3 		– Sell
-544
Closed -$11K – 5716
2025
Q2 		$11K Sell
544
-2,651
-83% -$32.7K ﹤0.01% 3925
2025
Q1 		$24.6K Buy
+3,195
New +$18.4K ﹤0.01% 2777

Other funds holding QNTM

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PTP
Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Tower Research Capital (TRC)'s QNTM Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Quantum Biopharma Class B Subordinate Voting Shares (QNTM) in Q2 2026, closing a stake of 71 shares — an estimated $343 sold.

Tower Research Capital (TRC) first reported a position in QNTM in Q1 2025 and held it in 3 quarters. The position peaked at $24.6K in Q1 2025. 26 funds tracked by Wall St. Rank hold QNTM as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining Quantum Biopharma Class B Subordinate Voting Shares position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 71 Quantum Biopharma Class B Subordinate Voting Shares shares in Q2 2026, an estimated $343.
  • Tower Research Capital (TRC) first reported a position in Quantum Biopharma Class B Subordinate Voting Shares in Q1 2025 and held it in 3 quarters.
  • Tower Research Capital (TRC)'s Quantum Biopharma Class B Subordinate Voting Shares position peaked at $24.6K in Q1 2025.
  • 26 funds tracked by Wall St. Rank held Quantum Biopharma Class B Subordinate Voting Shares as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.